Escala Medical

Executive Summary

Escala Medical is an Israeli med-tech company addressing pelvic organ prolapse (POP), a condition affecting millions of women worldwide. Traditional surgical repair often requires invasive procedures with lengthy recovery. Escala's Mendit system offers an FDA-cleared, incision-free outpatient procedure that restores pelvic support within minutes by placing small anchors in native ligaments. This minimally invasive approach enables rapid return to normal activities and is designed to be reimbursable, potentially expanding access to care. The company targets a large underserved market in women's health, with the global POP treatment market estimated at over $2 billion annually. Founded in 2020, Escala has raised $12M to commercialize Mendit and is now in early commercial stage. The device has been adopted by select urogynaecology clinics, and the company is focused on generating clinical evidence, building a sales pipeline, and securing insurance coverage. Key near-term catalysts include achieving meaningful recurring revenue, expanding indications or next-generation device approvals, and forming strategic partnerships with hospital networks. With a strong value proposition and FDA clearance, Escala is positioned for growth, though execution risk remains given its private, early-commercial status.

Upcoming Catalysts (preview)

• Q4 2026First annual revenue exceeding $5 million70% success
• Q2 2027FDA 510(k) clearance for additional indication or device iteration50% success
• Q3 2026Partnership with large hospital network or group purchasing organization60% success